12:00 AM
 | 
May 12, 2014
 |  BC Week In Review  |  Clinical News  |  Regulatory

Giotrif afatinib regulatory update

Germany's Federal Joint Commission (G-BA) issued a final benefit assessment for Giotrif afatinib from Boehringer Ingelheim to treat non-small cell lung cancer (NSCLC). According to Boehringer, G-BA said Giotrif has considerable benefit in previously untreated patients with exon 19 deletion EGFR gene mutations and...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >